These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

778 related items for PubMed ID: 31550937

  • 1. Monoclonal antibodies for the prevention of migraine.
    Raffaelli B, Neeb L, Reuter U.
    Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J, Manise M, Nonis R, Gérard P, Timmermans G.
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD.
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [Abstract] [Full Text] [Related]

  • 10. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 Aug; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X.
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H, Spare NM, Silberstein SD.
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [Abstract] [Full Text] [Related]

  • 17. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ.
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [Abstract] [Full Text] [Related]

  • 18. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A, Vaughn C, Rayhill M.
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.